drugset / Trial / NCT02218073
Pharmacokinetic Study of JNJ-42756493 in Healthy Participants
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the absolute bioavailability (the extent to which a drug or other substance becomes available to the body) of JNJ-42756493 following a single 10 milligram (mg) dose as an oral solution administered in combination with a single intravenous administration of a microdose (100 microgram \[mcg\]) of JNJ-61818549 and to evaluate the relative bioavailability of 10 mg JNJ-42756493 following an oral solution (reference) and a tablet (test) formulation in a crossover (method used to switch subjects from one study group to another in a clinical trial) design in healthy participants.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erdafitinib | Small molecule | 10 mg | Oral |
| Subject | JNJ-61818549 | Unknown | 100 ug | Intravenous |
Indications
No indication recorded.